Table 2 Baseline clinical data of 143 patients with in patients with stage III NSCLC

Asian

96

47

Age (yr, mean ± SD)

70.96 ± 10.27

74.49 ± 11.41

0.062

Sex

0.548

 Male (No.)

70 (72.92%)

32 (68.09%)

 Female

26 (27.08%)

15 (31.91%)

ECOG

0.709

 0–2

86 (89.58%)

37 (78.72%)

  > 2

10 (10.42%)

10 (21.28%)

Tumor type (%)

0.158

 ADC

56 (58.33%)

25 (53.19%)

 SCC

40 (41.67%)

22 (46.81%)

Therapeutic typology

0.081

 Surgery

8 (8.33%)

6 (12.77%)

 Chemotherapy

55 (57.3%)

34 (72.3%)

 Targeted therapy

34 (35.4%)

6 (12.8%)

 Immunotherapy

9 (9.4%)

3 (6.4%)

 Radiotherapy

5 (5.2%)

6 (12.8%)

Treatment line

0.721

 First line

78 (81.25%)

37 (78.7%)

 Subsequent lines

18 (18.75%)

10 (21.3%)

Smoking status

0.916

 Never smoker

54 (56.25%)

26 (55.32%)

 ever smoker

42 (43.75%)

21 (44.68%)